Standard BioTools Corp (LAB): Growth-Adjusted Market Cap to Net Income
Standard BioTools Inc. develops high-precision instruments for proteomic analysis using proprietary mass cytometry. The company's valuation relative to its growth rate demonstrates market dynamics where 0.00 serves as the base parameter value. Revenue is based on the sale of protein research systems and software. High barriers to entry are ensured by FDA certification and strong customer lock-in to proprietary consumables.
Standard BioTools Inc. (LAB) - metric breakdowns and financial figures
- current quotes and average value forecast:
- stock exchange capitalization data:
- company book value details:
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient Standard BioTools Inc.|LAB - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio fluidigm.com|LAB - Company Aggregate Debts|Debts to Book Capitalization Fluidigm|LAB - Company Long-Term Debt|Company Short-Term Indebtedness Standard BioTools|Immediate Liquidity Ratio fluidigm.com
- net income and valuation ratios data:
LAB - Net Profit|Projected Future Earnings Standard BioTools Inc.|LAB - Price to Earnings Ratio|Future Price to Earnings Multiple Standard BioTools Corp|LAB - PEG Multiple|Enterprise Value to Operating Income Before Depreciation Fluidigm|LAB - Operating profit before deduction of amortization|Earnings per share for the trailing year Standard BioTools|LAB - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months fluidigm.com|LAB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Standard BioTools Inc.
General company analysis:LAB Standard BioTools Inc
Steady demand for genomic analysis equipment from pharma behemoths and institutes makes Standard BioTools Inc. (LAB) a resilient asset. The current PEG ratio of 0.00 compares the market multiple with earnings growth: values below one signal that the company is undervalued relative to its expansion, indicating a potentially lucrative entry point for the investor.
Competitors of Standard BioTools Inc.
A - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Quest DGX|Growth-Adjusted Market Cap to Net Income Illumina Platform (ILMN)|Exact Sciences - PEG Multiple|Growth-Adjusted Market Cap to Net Income revvity.com RVTY|Bio-Rad (BIO) - Price/Earnings to Growth Ratio|NNNN - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Sterigenics|QuidelOrtho Inc. (QDEL) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple OPK (OPKO Health, Inc.)|Company Value to Earnings Growth Ratio CDNA|PEG Multiple MRVI (Maravai LifeSciences Holdings, Inc.)|PEG Multiple Fulgent Genetics Inc FLGT|CTKB - Price/Earnings to Growth Ratio|OSUR (OraSure Corp) - Growth-Adjusted P/E Ratio|XGN: PEG Multiple|Growth-Adjusted P/E Ratio MDXH|LUCD (Lucid Diagnostics) - PEG Multiple|PEG Multiple Prenetics Global Ltd|Price/Earnings to Growth Ratio Insight Molecular Diagnostics (IMDX)|TRIB (trinitybiotech.com) - Growth-Adjusted Payback Ratio|PEG Multiple PRPH (ProPhase Labs, Inc.)|AIMD: Growth-Adjusted P/E Ratio|CODX: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio HSCS (Heart Test Laboratories, Inc.)|BMRA: PEG Multiple|CDIO (Cardio Diagnostics Holdings) - Price/Earnings to Growth Ratio|ONCO (Onconetix, Inc.) - PEG Multiple|viraxbiolabs.com (VRAX) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Bluejay Diagnostics, Inc. (BJDX)|AWH - Price to Earnings Adjusted for Growth Rate|Accelerate Diagnostics, Inc - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio CNTG (Centogene NV)|ENZ - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Fresh2 Group Limited|gtglabs.com (GENE) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate 23andMe Holding Co (ME)|Price/Earnings to Growth Ratio Psychemedics Corp
